IGC (IGC Pharma) Other Stockholders Equity : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is IGC Pharma Other Stockholders Equity?

IGC Pharma's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $0.00 Mil.

IGC Pharma's quarterly Other Stockholders Equity declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

IGC Pharma's annual Other Stockholders Equity increased from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil) but then declined from Mar. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

IGC Pharma Other Stockholders Equity Historical Data

The historical data trend for IGC Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Other Stockholders Equity Chart

IGC Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Other Stockholders Equity

Get a 7-Day Free Trial

IGC Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

IGC Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

IGC Pharma Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (AMEX:IGC) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Executives

James P Moran	director	914 SPRING HILL ROAD, MCLEAN VA 22102
John Edward Lynch	director	14 PARK AVENUE, REHOBOTH BEACH DE 19971
Richard K Prins	director
Ram Mukunda	director, officer: Exec. Chairman & CEO
Claudia Grimaldi	officer: Vice president and PFO	PO BOX 60642, POTOMAC MD 20859
Rohit Goel	officer: Manager & PAO	PO BOX 60642, POTOMAC MD 20859
John Cherin	officer: CFO, Treasurer and PAO	662 LIVE OAK DRIVE, MCLEAN VA 22101
Shu Kwong Ngai	director, officer: Interim CFO	4336 MONTGOMERY AVENUE, BETHESDA MD 20814
Ranga C Krishna	director	330 THORNTON ROAD, ENGLEWOOD X1 07631
Sudhakar V Shenoy	director	10411 MOTOR CITY DRIVE, BETHESDA MD 20817
Suhail Nathani	director	INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814
Nisswa Acquisition Master Fund Ltd.	10 percent owner	C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Smith Edward B Iii	10 percent owner	C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036
Ag Ubs	10 percent owner	600 WASHINGTON BLVD., STAMFORD CT 06901
Pine River Master Fund Ltd.	10 percent owner	C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305